Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 27Lymphoid 8Thoracic 2Sarcoma 2Other hematologic neoplasm 2Other solid neoplasm 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Sarcoma 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Leukemia-Lymphoma, Adult T-Cell 1Kidney Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Glioma 1Colorectal Neoplasms 1Breast Neoplasms 1Bone Neoplasms 1

Interventions

Oxaliplatin 778Fluorouracil 637Capecitabine 573Gemcitabine 478Leucovorin 458Irinotecan 444Bevacizumab 443Cisplatin 337Radiotherapy 282Cetuximab 251Paclitaxel 180S 1 (combination) 175pembrolizumab 173Docetaxel 156Drug Therapy 147Nivolumab 146sintilimab 143tislelizumab 130apatinib 130130-nm albumin-bound paclitaxel 127Folfox protocol 120durvalumab 119Albumin-Bound Paclitaxel 117camrelizumab 107lenvatinib 106Panitumumab 106Surgical Procedures, Operative 102regorafenib 101Sorafenib 99Radiation 88

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lomustine × Gastrointestinal × Clear all
NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

Actuate Therapeutics Inc.

Phase 2 Active not recruiting
350 enrolled
BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡